Alpine Immune Sciences Announces Poster Presentation at 2017 ACR/ARHP Annual Meeting
SEATTLE, WA–(BUSINESS WIRE)—September 20, 2017– Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing treatments for autoimmune/inflammatory diseases and cancer, today announced a planned poster presentation highlighting recent data from a preclinical study evaluating dual ICOS/CD28 antagonists generated by the Company’s vlgD™ platform at the upcoming 2017 American College of Rheumatology Annual Meeting being held on November 3-8, 2017, in San Diego CA.
Details of the poster presentation are as follows:
- Abstract Title: A Dual ICOS/CD28 Antagonist ICOSL Variant Ig Domain (vIgD™) Potently Suppresses Mouse Collagen-Induced Arthritis and Human Xenograft Graft Vs. Host Disease (GvHD)
- Session Title: Rheumatoid Arthritis – Animal Models Poster II
- Date and Time: November 6, 2017 at 9:00 a.m. – 11:00 a.m. PT
- Session Type: ACR Poster Session B
- Abstract: #1328
The full abstract is available online at https://www.rheumatology.org/Annual-Meeting under the “Abstracts” section.
About Alpine Immune Sciences, Inc.
Alpine Immune Sciences, Inc. is focused on developing novel protein-based immunotherapies using its proprietary Variant Ig Domain™ vIgD™ platform technology. The vIgD platform is designed to interact with multiple targets, including many present in the immune synapse. Alpine’s vIgDs are developed using a process known as directed evolution, which produces proteins capable of either enhancing or diminishing an immune response and thereby may potentially apply therapeutically to cancer, autoimmune, and inflammatory diseases. Alpine has also developed TIP™ technology, based on the vIgD platform, to potentially enhance engineered cellular therapies. In October 2015, Alpine signed a worldwide research and license agreement with Kite Pharma, Inc. (KITE) for up to $535 million in up front and potential milestone payments plus royalties on resulting sales. For more information visit www.alpineimmunesciences.com/.
This release contains forward-looking statements regarding Alpine including Alpine’s platform technology, potential therapies, clinical and regulatory objectives. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “plan,” “intend,” and other similar expressions among others. Actual results could differ materially and these statements are subject to important risks, including that Alpine’s discovery-stage and pre-clinical programs do not advance into the clinic or result in approved products on a timely or cost-effective basis or at all. Alpine’s pipeline programs, including the ALPN-101 program, are in pre-clinical development, and the process by which a pre-clinical therapeutic candidate could potentially lead to an approved therapeutic is long and subject to significant risks and uncertainties. Applicable risks and uncertainties include those relating to our pre-clinical and potential clinical research and other risks identified under the heading “Risk Factors” are included in Alpine’s filings with the SEC. Alpine undertakes no obligation to update forward-looking statements as a result of new information or otherwise.